Brief: Denali Therapeutics Q3 Net Income USD -107.192 Million
06/11/2024 21:01
Nov 06 (Reuters) - Denali Therapeutics Q3 operating expenses USD 123.187 million. * Q3 operating income USD -123.187 million * Q3 basic EPS USD -0.63
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers